We recently updated our Privacy Notice and Terms of Use.
Med-IQ
PCSK9 Inhibitors: For Whom, When, and Why
Audiocast Audiocast

PCSK9 Inhibitors: For Whom, When, and Why


This activity was developed in collaboration with Cleveland Clinic Foundation Center for Continuing Education and Med-IQ.

Cleveland Clinic      Med-IQ
 

Released:
7/17/18
Expires:
7/16/19
PDF:

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
7/17/18

Expires:
7/16/19

PDF:

Maximum Credits:
0.5
Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
7/17/18
Expires:
7/16/19
PDF:


Maximum Credits:
0.5


Overview: In this audiocast, expert faculty discuss current clinical evidence regarding the benefit of adding a PCSK9 inhibitor to statin therapy in patients with cardiovascular risk and dyslipidemia. Additionally, key criteria for selecting patients for PCSK9 inhibitor therapy as well as determining optimal timing for initiating treatment are explored.

CME Information:

Faculty
Leslie Cho, MD
Section Head, Preventive Cardiology and Rehabilitation
Director, Women’s Cardiovascular Center
Cleveland Clinic
Cleveland, OH

Steven Nissen, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Chairman, Robert and Suzanne Tomsich Department of Cardiovascular Medicine
Cleveland Clinic
Cleveland, OH

Activity Planners
Activity Director

Katherine J. Hoercher, RN, FAHA
Senior Director
Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH

Erin Grothey, MS
Clinical Content Manager
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Describe clinical trial data for PCSK9 inhibitor therapeutics
  • Compare guideline recommendations when choosing which patients should receive PCSK9 inhibitors
  • Discuss the patient groups that would most benefit from PCSK9 inhibitor therapy

Target Audience
This activity is intended for cardiologists, endocrinologists, primary care physicians, physician assistants, advanced practice nurses, pharmacists, and other healthcare professionals involved in the care of patients with elevated cholesterol levels.
 
Statement of Need
The first PCSK9 inhibitors were approved in the summer of 2015, creating a significant change in the treatment landscape for patients with dyslipidemia. Identifying at-risk patients who are candidates for this treatment, as well as understanding when and how to initiate it, remains complex because of the wealth of clinical data and varying practice recommendations from multiple professional associations. It is important that healthcare providers receive updates on the current management of dyslipidemia to achieve optimal outcomes in this patient population. Although recent prospective data support the clinical utility of PCSK9 inhibitors, many important unanswered questions remain related to the implications of long-term use and approaches for identifying optimal candidates for treatment.
 
Collaboration Statement
This activity was developed in collaboration with Cleveland Clinic Foundation Center for Continuing Education and Med-IQ.
Cleveland Clinic      Med-IQ

Accreditation/Designation Statements
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

ACPEMed-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hour (0.05 CEUs) of credit for pharmacists. ACPE #0476-0000-18-003-H01-P. This knowledge-based activity is designed for all pharmacists.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CME/CPE material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: July 17, 2018
Expiration Date: July 16, 2019
Estimated Time to Complete This Activity: 30 minutes
 
Disclosure Statement
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. 
 
Leslie Cho, MD
Consulting fees/advisory boards: Amgen
Contracted research: Amgen, Esperion, Sanofi-aventis U.S. Inc.
 
Katherine J. Hoercher, RN, FAHA, has indicated no real or apparent conflicts.
 
Steven Nissen, MD, has indicated no real or apparent conflicts.  
 
The peer reviewers and activity planners have no financial relationships to disclose.

Contact Information 
For questions or comments about this activity or CPE contact hours, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

To contact the CME provider, call 216-444-9990.
 
Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Browser
Microsoft Internet Explorer 8.0 or later

Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
 
Google Chrome - latest version
Download: http://www.google.com/chrome
 
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support
 
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.  

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Amgen.

Copyright
© 2018 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.